Shire PLC (LON:SHP)‘s stock had its “buy” rating restated by stock analysts at Jefferies Group LLC in a research report issued on Friday. They presently have a GBX 6,600 ($82.48) price objective on the biopharmaceutical company’s stock. Jefferies Group LLC’s price objective points to a potential upside of 38.57% from the stock’s current price.

A number of other equities research analysts have also recently weighed in on the company. Liberum Capital reaffirmed a “buy” rating and set a GBX 5,500 ($68.73) price target on shares of Shire PLC in a report on Friday. Deutsche Bank AG reaffirmed a “buy” rating on shares of Shire PLC in a report on Friday. Citigroup Inc. reaffirmed a “buy” rating on shares of Shire PLC in a report on Friday. Shore Capital reaffirmed a “buy” rating on shares of Shire PLC in a report on Friday, February 10th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a GBX 5,400 ($67.48) price target on shares of Shire PLC in a report on Wednesday, February 8th. Fifteen equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of GBX 6,048.86 ($75.59).

Analyst Recommendations for Shire PLC (LON:SHP)

Shire PLC (LON:SHP) opened at 4814.00 on Friday. The company’s 50-day moving average price is GBX 4,576.51 and its 200 day moving average price is GBX 4,788.88. The firm’s market capitalization is GBX 43.34 billion. Shire PLC has a 52-week low of GBX 2,707.19 and a 52-week high of GBX 5,377.00.

The business also recently declared a dividend, which will be paid on Tuesday, April 25th. Stockholders of record on Thursday, March 9th will be given a GBX 20.64 ($0.26) dividend. This is a positive change from Shire PLC’s previous dividend of $3.51. This represents a dividend yield of 0.43%. The ex-dividend date is Thursday, March 9th.

This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The correct version of this report can be accessed at

In related news, insider Olivier Bohuon purchased 141 shares of Shire PLC stock in a transaction dated Friday, December 16th. The shares were acquired at an average cost of GBX 4,528 ($56.59) per share, for a total transaction of £6,384.48 ($7,978.61).

About Shire PLC

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with's FREE daily email newsletter.